Newsbenzinga
Compass Pathways’ Psilocybin Treatment Shows Lasting Benefits in Treatment-Resistant Depression
· Published
Article summary
Compass Pathways surges 11% after COMP360 Phase 3 trial shows durable 52-week relief for treatment-resistant depression.
An excerpt from the original article.
Comments —
Loading comments…